Foundation of APREX and generation 1 & 2 of the MEMS
First MEMS-based peer-reviewed publication in JAMA
Generation 3 of the MEMS
First phase IV clinical study sponsored by Pfizer comparing anti-hypertensive treatments forgiveness.
Generation 4 of the MEMS
First audit by a large pharma company (Ely Lilly)
Foundation of AARDEX in Switzerland and acquisition of APREX
Generation 5 of the MEMS
First ISO9001 certification
Opening of the AARDEX research centre in Belgium
First FDA filing of MEMS data from a large scale Phase II/III drug development program in HIV
Generation 6 of the MEMS
Launch of medAmigo
Building of the largest repository of dosing history data and the AARDEX knowledge centre
First deployment of MEMS and medAmigo in large scale drug development of new, all oral, HCV therapies (multi-company, multi-study, multi-country, multi-site).
Aquisition of AARDEX by MWV
First large scale adherence-enhancing program based on MEMS and medAmigo in resource-limited setting sponsored by the Bill & Melinda Gates Foundation.
MWV merger with Rocktenn to become Westrock
Generation 8 of the MEMS family of smart packages
MBO from WestRock
HQ AARDEX Group operating from Belgium with subsidiary AARDEX Group Switzerland